Prelude Therapeutics Inc PRLD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 06/24/22 EDT
5.46UNCH (UNCH)
Volume
181,210
Close
5.46quote price arrow up+0.17 (+3.21%)
Volume
1,192,729
52 week range
3.87 - 43.55
Loading...
  • Open5.31
  • Day High5.74
  • Day Low5.23
  • Prev Close5.29
  • 52 Week High43.55
  • 52 Week High Date09/02/21
  • 52 Week Low3.87
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap260.44M
  • Shares Out47.70M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-56.14

KEY STATS

  • Open5.31
  • Day High5.74
  • Day Low5.23
  • Prev Close5.29
  • 52 Week High43.55
  • 52 Week High Date09/02/21
  • 52 Week Low3.87
  • 52 Week Low Date05/09/22
  • Market Cap260.44M
  • Shares Out47.70M
  • 10 Day Average Volume0.18M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-56.14

RATIOS/PROFITABILITY

  • EPS (TTM)-2.58
  • P/E (TTM)-2.12
  • Fwd P/E (NTM)-2.78
  • EBITDA (TTM)-120.994M
  • ROE (TTM)-38.77%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Prelude Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Prelude Therapeutics Inc. is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. The Company’s product candidate pipeline includes PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT3645. PRT543 is in a Phase I clinical trial in advanced solid tumors and select myeloid malignancies. PRT811 is a being studied in a Phase I clinical trial in unselected patients with solid...
Paul Friedman M.D.
Independent Chairman of the Board
Krishna Vaddi Ph.D.
Chief Executive Officer, Founder, Director
Jane Huang M.D.
President, Chief Medical Officer
Laurent Chardonnet
Chief Financial Officer
Andrew Combs Ph.D.
Executive Vice President, Head of Chemistry
Address
200 Powder Mill Road
Wilmington, DE
19803
United States

Top Peers

SYMBOLLASTCHG%CHG
OTLK
Outlook Therapeutics Inc
1.09+0.06+5.83%
TNYA
Tenaya Therapeutics Inc
6.16-0.18-2.84%
KALV
Kalvista Pharmaceuticals Inc
10.33-0.03-0.29%
RLYB
Rallybio Corp
8.00+0.64+8.70%
LXRX
Lexicon Pharmaceuticals Inc
2.03+0.04+2.01%